Benitec Biopharma Inc. (NASDAQ: BNTC) had $180.0 million in cash and cash equivalents at June 30, 2026, while its BB-301 program progressed through clinical follow-up, enrollment and regulatory planning.
BioMarin appointed Robert Plenge to its board and granted him 6,140 restricted stock units valued at $400,000. The award will vest immediately before the company’s next regular annual meeting, while his committee appointment and standard director fees define the stated terms for investors.Key HighlightsRobert …
BIOMARIN PHARMACEUTICAL INC (NASDAQ: BMRN) awarded director Robert M Plenge 6,140 shares at $0 per share. The transaction was recorded on Sep 10, 2026.
Investor Presentation Set for Conference Meetings
Portnoy Adam D. was awarded 59,681 shares of Diversified Healthcare Trust (NASDAQ: DHC) on 10 September 2026. Following the transaction, the trust’s director held 487,239 shares, while the transaction represented about 12.2% of that holding.
Edwards Lifesciences Corp (NYSE: EW) recorded a forfeiture of 253 shares by Andrew M. Dahl at $84.37 per share. Dahl is the company’s SVP and Corporate Controller.
● Astrana Health reported second-quarterRevenueof $972.5 million, up 49% year over year, and raised full-year 2026 guidance to revenue of $4.1 billion and adjusted EBITDA of $280 million.
Biotech and health technology rarely move as a single block, and that is exactly the point. As of mid-September 2026, theNasdaqComposite houses companies at every stage of the healthcare life cycle, from profitable commercial franchises to pre-revenue clinical developers burning cash toward a first …
Biotech rarely moves as a single block, and this quintet proves it. Grouped only by their Nasdaq listing and their place in health innovation, CG Oncology (NASDAQ:CGON), Pasithea Therapeutics (NASDAQ:KTTA), GRAIL (NASDAQ:GRAL), AbCelleraBiologics(NASDAQ:ABCL) and Belite Bio (NASDAQ:BLTE) sit at wildly different points on the …
● Entera Bio closed a BVF Partners-led privatePlacementin July 2026 at $2.04 per share, extending its cash runway into 2030 ahead of a planned Phase 3 start for oral-peptide candidate EB613.